ISDA

Deposition Date 2020-12-01

Release Date 2020-12-16

Last Version Date 2024-11-13

Entry Detail

PDB ID:

7B3O

Keywords:

ANTIVIRAL PROTEIN

Title:

Crystal structure of the SARS-CoV-2 RBD in complex with STE90-C11 Fab

Biological Source:

Source Organism:

Severe acute respiratory syndrome coronavirus 2 (Taxon ID: 2697049)
Homo sapiens (Taxon ID: 9606)

Host Organism:

Trichoplusia ni

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.00 Å

R-Value Free:

0.22

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

C 1 2 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Spike protein S1
Gene (Uniprot):S
Chain IDs:A (auth: E)
Chain Length:205
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTC2 Pfam ID:PF09408

Polymer Type:polypeptide(L)
Molecule:Heavy Chain of Fab Fragment
Chain IDs:C (auth: H)
Chain Length:228
Number of Molecules:1
Biological Source:Homo sapiens

Polymer Type:polypeptide(L)
Molecule:Light Chain of Fab Fragment
Chain IDs:B (auth: L)
Chain Length:215
Number of Molecules:1
Biological Source:Homo sapiens

Primary Citation

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.

Bertoglio, F, Fuhner, V, Ruschig, M, Heine, P.A, Abassi, L, Klunemann, T, Rand, U, Meier, D, Langreder, N, Steinke, S, Ballmann, R, Schneider, K.T, Roth, K.D.R, Kuhn, P, Riese, P, Schackermann, D, Korn, J, Koch, A, Chaudhry, M.Z, Eschke, K, Kim, Y, Zock-Emmenthal, S, Becker, M, Scholz, M, Moreira, G.M.S.G, Wenzel, E.V, Russo, G, Garritsen, H.S.P, Casu, S, Gerstner, A, Roth, G, Adler, J, Trimpert, J, Hermann, A, Schirrmann, T, Dubel, S, Frenzel, A, Van den Heuvel, J, Cicin-Sain, L, Schubert, M, Hust, M, Bertoglio, F, Fuhner, V, Ruschig, M, Heine, P.A, Abassi, L, Klunemann, T, Rand, U, Meier, D, Langreder, N, Steinke, S, Ballmann, R, Schneider, K.T, Roth, K.D.R, Kuhn, P, Riese, P, Schackermann, D, Korn, J, Koch, A, Chaudhry, M.Z, Eschke, K, Kim, Y, Zock-Emmenthal, S, Becker, M, Scholz, M, Moreira, G.M.S.G, Wenzel, E.V, Russo, G, Garritsen, H.S.P, Casu, S, Gerstner, A, Roth, G, Adler, J, Trimpert, J, Hermann, A, Schirrmann, T, Dubel, S, Frenzel, A, Van den Heuvel, J, Cicin-Sain, L, Schubert, M, Hust, M, Bertoglio, F, Fuhner, V, Ruschig, M, Heine, P.A, Rand, U, Klunemann, T, Meier, D, Langreder, N, Steinke, S, Ballmann, R, Schneider, K, Roth, K.D.R, Kuhn, P, Riese, P, Schackermann, D, Korn, J, Koch, A, Zock-Emmenthal, S, Becker, M, Scholz, M, Moreira, G.M.S.G, Wenzel, E.V, Russo, G, Garritsen, H.S, Casu, S, Gerstner, A, Roth, G, Hermann, A, Schirrmann, T, Dubel, S, Frenzel, A, Cicin-Sain, L, Schubert, M, Hust, M.Show

Cell Rep 36 109433 109433 (2021)

PMID: 34273271 DOI: 10.1016/j.celrep.2021.109433

Abstact

The novel betacoronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) causes a form of severe pneumonia disease called coronavirus disease 2019 (COVID-19). To develop human neutralizing anti-SARS-CoV-2 antibodies, antibody gene libraries from convalescent COVID-19 patients were constructed and recombinant antibody fragments (scFv) against the receptor-binding domain (RBD) of the spike protein were selected by phage display. The antibody STE90-C11 shows a subnanometer IC50 in a plaque-based live SARS-CoV-2 neutralization assay. The in vivo efficacy of the antibody is demonstrated in the Syrian hamster and in the human angiotensin-converting enzyme 2 (hACE2) mice model. The crystal structure of STE90-C11 Fab in complex with SARS-CoV-2-RBD is solved at 2.0 Å resolution showing that the antibody binds at the same region as ACE2 to RBD. The binding and inhibition of STE90-C11 is not blocked by many known emerging RBD mutations. STE90-C11-derived human IgG1 with FcγR-silenced Fc (COR-101) is undergoing Phase Ib/II clinical trials for the treatment of moderate to severe COVID-19.

Legend

Protein

Chemical

Disease

Primary Citation of related structures